Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01913106 · ClinicalTrials.gov registry record · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
A Phase 1 study of Prostatic Neoplasms, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01913106: Recruiting Phase 1 study of Prostatic Neoplasms, sponsored by The Methodist Hospital Research Institute.
NCT01913106 is a Phase 1 study of Prostatic Neoplasms that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 25 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01913106, a Phase 1 study of Prostatic Neoplasms, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the development of metastatic disease and the control of preexisting metastasis.
Conditions Studied
Interventions
- DRUG HSV-tk +Valacyclovir in Combination with Brachytherapy
Study Locations (1)
Texas
- Houston Methodist - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT01913106 shows while recruiting
NCT01913106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which HSV-tk +Valacyclovir in Combination with Brachytherapy is the first listed.
NCT01913106 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01913106 about?
NCT01913106 is a clinical study titled "HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer". The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully im...
What is the current status of trial NCT01913106?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-06. Estimated completion is 2028-12.
What conditions does trial NCT01913106 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT01913106?
The interventions under investigation include: HSV-tk +Valacyclovir in Combination with Brachytherapy (DRUG).
Who is sponsoring clinical trial NCT01913106?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01913106 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01913106's enrollment target sits among peer trials
25 53rd of 65 higher than 12 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
RECRUITING · Phase 1
-
A Study of DM002 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- NCT02358187 · 25 participants · Phase 2
A Vaccine Trial for Low Grade Gliomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia